Fig. 4From: ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE studyOCS dosage reduction during benralizumab treatment. Data are expressed as median in mg prednisone equivalentBack to article page